| Balance Sheets | 2025-07-31 | |||
|---|---|---|---|---|
| Cash and cash equivalents | 13,178,305 | |||
| Marketable equity securities | 261,853 | |||
| Warrant asset tnf - current | 820,000 | |||
| Convertible note receivable femasys - current | 4,608,000 | |||
| Prepaid expenses and other current assets | 238,180 | |||
| Total current assets | 19,106,338 | |||
| Intangible asset | 1,549,427 | |||
| Investment in preferred stock tnf | 19,635,000 | |||
| Warrant asset tnf - non current | 2,966,000 | |||
| Warrant asset femasys | 1,846,000 | |||
| Other assets | 7,688 | |||
| Total other assets | 26,004,115 | |||
| Total assets | 45,110,453 | |||
| Accounts payable | 465,209 | |||
| Accrued expenses | 595,656 | |||
| Total current liabilities | 1,060,865 | |||
| Long-term portion of accrued expenses | 0 | |||
| Warrant liabilities | 458,000 | |||
| Total other liabilities | 458,000 | |||
| Total liabilities | 1,518,865 | |||
| Convertible preferred stock-Series BPreferred Stock | 0 | |||
| Preferred stock value-Series APreferred Stock | 0 | |||
| Common stock authorized 200,000,000 shares, 0.0001 par value 21,672,095 shares issued and 6,795,779 shares outstanding as of july 31, 2025 and april 30, 2025, respectively | 2,167 | |||
| Additional paid-in capital | 181,550,139 | |||
| Accumulated deficit | -93,329,056 | |||
| Treasury stock, at cost, 14,876,316 shares as of july 31, 2025, and april 30, 2025, respectively | 44,607,916 | |||
| Accumulated other comprehensive loss | -23,746 | |||
| Total stockholders' equity | 43,591,588 | |||
| Total liabilities, convertible preferred stock and stockholders' equity | 45,110,453 | |||
PharmaCyte Biotech, Inc. (PMCB)
PharmaCyte Biotech, Inc. (PMCB)